Clinical overview of nedocromil sodium.
Nedocromil sodium is a novel anti-inflammatory agent that has been demonstrated to significantly improve pulmonary function and decrease bronchial hyperreactivity in asthmatic patients. Currently available only as an inhaled drug, nedocromil sodium has an excellent safety profile, the only adverse effect being a slightly unpleasant taste. Nedocromil sodium has been used as a replacement for sustained-release theophylline therapy; the overall efficacy of nedocromil sodium is at least equivalent to that of theophylline, with less adverse effects occurring in those patients treated with nedocromil sodium rather than with theophylline. Nedocromil sodium also appears to be equal in efficacy to low doses of beclomethasone when employed in patients with mild to moderate asthma. Addition of nedocromil sodium to an ongoing regimen of beclomethasone may also allow for reduction in the dosage of inhaled corticosteroid. The overall safety of therapy with nedocromil sodium suggests that it be considered as initial therapy for those patients having mild to moderate asthma.
König
P
P
Department of Child Health, University Hospital, University of Missouri, Columbia 65212, USA.
D000280:Administration, Inhalation; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D017835:Nedocromil / Q000276:immunology / Q000627:therapeutic use*; D012720:Severity of Illness Index
D017835:Nedocromil; D001507:Beclomethasone